Step-wise loss of antidepressant effectiveness with repeated antidepressant trials in bipolar II depression

Bipolar Disorders

Volumn 18, Issue 7, 2016, Pages 563-570

  Amsterdam, Jay D ^a   Lorenzo Luaces, Lorenzo ^a,b,c   DeRubeis, Robert J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

antidepressant; bipolar disorder; depression; drug tolerance; lithium; loss of response; SNRI; SSRI; tachyphylaxis; treatment resistant depression; venlafaxine

Indexed keywords

LITHIUM CARBONATE; MOOD STABILIZER; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BIPOLAR II DISORDER; CAUCASIAN; CLINICAL GLOBAL IMPRESSION SCALE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DSM-IV-TR; EXPLORATORY RESEARCH; FEMALE; HAMILTON DEPRESSION RATING SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; STEP WISE INCREASE; STEP WISE MULTIPLE REGRESSION; TREATMENT DURATION; TREATMENT RESPONSE; BIPOLAR DISORDER; CLASSIFICATION; COMBINATION DRUG THERAPY; DRUG MONITORING; DRUG TOLERANCE; PROCEDURES; SECONDARY PREVENTION; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DOUBLE-BLIND METHOD; DRUG MONITORING; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; REMISSION INDUCTION; SECONDARY PREVENTION; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 84995563889     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12442     Document Type: Article

References (41)

1. Amsterdam JD, Maislin G, Potter L. Fluoxetine efficacy in treatment resistant depression. Prog Neuro-Psychopharmacol Biol Psychiat. 1994;18:243–261.
2. Amsterdam JD, Shults J. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?. J Affect Disord. 2009;115:234–240.
3. Posternak MA, Zimmerman M. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors. J Clin Psychiatry. 2005;66:705–707.
4. Solomon DA, Leon AC, Mueller TI, et al. Tachyphylaxis in unipolar major depressive disorder. J Clin Psychiatry. 2005;66:283–290.
5. Sharma V. Loss of response to antidepressants and subsequent refractoriness: diagnostic issues in a retrospective case series. J Affect Disord. 2001;64:99–106.
6. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr. 2006;11:12–21.
7. Thase ME, Haight BR, Richard N, et al. Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: A meta-analysis of original data from 7 randomized controlled trials. J Clin Psychiatry. 2005;66:974–981.
8. Leykin Y, Amsterdam JD, DeRubeis RJ, Gallop R, Shelton RC, Hollon SD. Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. J Consult Clin Psychol. 2007;75:267–276.
9. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiat 2006;163:1905–1917.
10. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
11. Amsterdam JD, Shults J. MAOI efficacy and safety in advanced stage treatment-resistant depression–a retrospective study. J Affect Disord. 2005;89:183–188.
12. Zimmerman M, Thongy T. How often Do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? J Clin Psychiatry. 2007;68:1271–1276.
13. Thase ME. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234–241.
14. Smeraldi E, Zanardi R, Benedetti F, Bella DD, Perez J, Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol Psychiatry. 1998;3:508–511.
15. Pollock B. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacol. 2000;23:587–590.
16. Fava M. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161–1172.
17. McGrath P. Tranylcypromine vs venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. Am J Psychiatry. 2006;163:1531–1541.
18. Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Safety and effectiveness of continuation antidepressant vs mood stabilizer monotherapy for relapse-prevention of bipolar II depression: a randomized, double-blind, parallel-group, prospective study. J Affect Disord. 2015;185:31–37.
19. Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Short-term venlafaxine v. lithium monotherapy for bipolar type II major depressive episodes: effectiveness and mood conversion rate. Br J Psychiatry. 2016;208:359–365.
20. First MB, Spitzer RL, Gibbon M, Williams JB. Structured Clin Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/ PSY SCREEN). New York: NY, Biometrics Research, New York State Psychiatric Institute; 2001.
21. Williams JBW. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry. 1988;45:742–747.
22. Baber N. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH). Br J Clin Pharmacol. 1994;37:401–404.
23. Nierenberg AA, Amsterdam J. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry. 1990;51:39–47.
24. Nierenberg A, Keck P, Samson J, Rothschild A, Schatzberg A. Methodological considerations for the study of treatment-resistant depression. Adv Neuropsychiatr Psychopharmacol. 1991;2:1–12.
25. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychistry. 1978;133:429–435.
26. Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs; 1976.
27. Lieb J, Balter A. Antidepressant tachyphylaxis. Med Hypotheses. 1984;15:279–291.
28. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994;14:419–423.
29. Nierenberg AA, Papakostas GI, Petersen T, et al. Nortriptyline for treatment-resistant depression. J Clin Psychiatry. 2003;64:35–39.
30. Amsterdam JD, Williams D, Michelson D, et al. Tachyphylaxis after repeated antidepressant drug exposure in patients with recurrent major depressive disorder. Neuropsychobiol. 2009;59:227–233.
31. Fava GA. Can long-term treatment with antidepressant drugs worsen the course of depression? J Clin Psychiatry. 2003;64:123–133.
32. Whitaker R. Anatomy of an epidemic: magic bullets, psychiatric drugs, and the astonishing rise of mental illness in America. New York: Crown Publishers; 2011.
33. Jacobs N, Kenis G, Peeters F, Derom C, Vlietinck R, van Os J. Stress-related negative affectivity and genetically altered serotonin transporter function. Arch Gen Psychiatry. 2006;63:989–996.
34. Neumeister A, Hu X-Z, Luckenbaugh DA, et al. Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry. 2006;63:978–986.
35. Kim DK, Lim S-W, Lee S, et al. Serotonin transporter gene polymorphism and antidepressant response. NeuroReport. 2000;11:215–219.
36. Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:383–386.
37. Murphy GM, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61:1163–1169.
38. Biggio G, Dazzi L, Biggio F, et al. Molecular mechanisms of tolerance to and withdrawal of GABAA receptor modulators. Eur Neuropsychopharmacol. 2003;13:411–423.
39. Bonavita CD, Bisagno V, Bonelli CG, Acosta GB, Rubio MC, Wikinski SI. Tolerance to the sedative effect of lorazepam correlates with a diminution in cortical release and affinity for glutamate. Neuropharmacol. 2002;42:619–625.
40. Simpson GM, Lindenmayer J-P. Extrapyramidal symptoms in patients treated with risperidone. J Clin Psychopharmacol. 1997;17:194–201.
41. Blanco C, Laje G, Olfson M, Marcus SC, Pincus HA. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002;159:1005–1010.